Homburger advised the shareholders of Evax AG on the sale to Boehringer Ingelheim

Boehringer Ingelheim acquired Evax AG, a Swiss biotech company focused on equine health. Founded more than a decade ago at the University of Zurich, Evax has been exploring the use of therapeutic vaccines to address significant unmet needs in horses, particularly for the treatment of allergic skin diseases.

The Homburger team advising the shareholders of Evax AG was co-led by Luca Dal Molin (IP/IT) and Karin Mattle (Corporate/M&A) and included Florian Bruggisser, Matteo Gasser (both Corporate/M&A), Reto Heuberger and Philippe Weber (both Tax), as well as Philippe Baumann (IP/IT).